The peptide market is forming faster than the trust layer.

Defensible market facts

• Grand View Research publicly reports Australia peptide therapeutics revenue of US$1.906B in 2025, projected to reach US$3.711B by 2033, with 7.8% CAGR from 2026 to 2033.
• McDermott's April 2026 peptide regulation deck cites the global peptide therapeutics market at US$140.86B in 2025 and US$294.58B projected for 2033.
• TIME and NPR both reported in February 2026 that social media, wellness influencers, and celebrity discussion are pushing peptides into mainstream awareness.
• The Week and GZERO reported that US imports of hormone and peptide compounds from China reached US$328M in the first three quarters of 2025, up from US$164M in the same period a year earlier.
• Brandwatch-based looksmaxxing coverage reported more than 806,000 mentions from September 2025 to early 2026, showing how appearance-led self-optimization demand has become a search and social channel.

Initial evidence base

The local March 2026 crawl tracked Australian and New Zealand peptide storefront candidates, Shopify stores, custom storefronts, WordPress stores, and adjacent wellness operators. This static launch uses that crawl as a source snapshot, not as final live proof.

What the report will measure

• How many vendors publish batch records before checkout.
• How many COAs are current and tied to a batch.
• How many vendors show Australian operation evidence beyond copy.
• How many suppliers offer payment recourse if the order fails.
• How many correction requests receive useful responses.

The commercial thesis

The commercial opening is not louder peptide advertising. It is owning the proof moment before a buyer trusts any store. That only compounds if the rubric, ownership, correction path, and evidence standard are public.

Reference sources

• TGA - Understanding responsibilities for unapproved peptide products: TGA names BPC-157, GHK-Cu, TB-500, retatrutide and CJC-1295 as examples of unapproved peptide products and warns that unclear labelling/code-only products may not be released under the Personal Importation Scheme.
• TGA - GLP-1 RA pharmacy compounding changes: TGA states amendments apply to medicines containing GLP-1 RA analogues compounded on or after 1 October 2024.
• TGA - Manufacturing, supplying and advertising compounded medicines lawfully: TGA guidance explains compounding, supply, advertising, GLP-1 analogue restrictions, IV therapy requirements, and exemptions.
• TGA - Switch Nutrition infringement notices: TGA issued 4 infringement notices totalling $79,200 to Switch Nutrition Pty Ltd for alleged unlawful advertising of therapeutic goods.
• TGA - Victorian fined for allegedly importing unapproved peptide: TGA issued one $3,756 infringement notice to a Victoria-based individual for alleged unlawful importation of a peptide.
• TGA and ABF - Three Victorians arrested after steroids and peptides seizure: Joint ABF/TGA release says more than $2M worth of PIEDs, steroids and peptide products were seized in an alleged importation syndicate investigation.
• TGA - Your Solution Compounding Pharmacy undertaking: TGA accepted a court-enforceable undertaking regarding advertising of prescription-only compounded medicines for weight loss.
• Peptide Dossier - Peptide Sciences shutdown analysis: Secondary source reporting the March 2026 Peptide Sciences shutdown, pending-order uncertainty, and the reported Grips Intelligence revenue estimate.
• TGA - $10 million Peptide Clinics penalty: TGA says the Federal Court ordered Peptide Clinics Australia, Peptide Clinics Pty Ltd, to pay $10 million for advertising breaches involving medicines, including prescription-only medicines.
• TGA - NSW-based individual infringement notices: TGA issued 5 infringement notices totalling $19,800 to a NSW-based individual for alleged unlawful importation of unapproved prescription-only medicines.
• TGA - 6 individuals infringement notices: TGA issued 11 infringement notices totalling $43,560 to 6 individuals for alleged unlawful importation of unapproved therapeutic goods and alleged unlawful advertising.
• FDA - Concerns with unapproved GLP-1 drugs: FDA states retatrutide and cagrilintide cannot be used in compounding under US federal law and warns counterfeit products may contain wrong, too little, too much, or no active ingredient.
• Eli Lilly - Identify real Lilly medicine: Lilly's counterfeit-medicine page warns that fake or counterfeit GLP-1 products are promoted online and may contain insulin, saline, or unknown products.
• Pure Peptides Australia - About us: Pure Peptides Australia says it is an Australian-based supplier of research peptides with third-party testing, documentation, COAs, and batch documentation.
• Aussie Peptide Hub - Homepage: Aussie Peptide Hub says products are third-party tested at 99%+ purity, COAs are available upon request, and products ship from within Australia.
• Prime Labs AU - Homepage: Prime Labs AU publishes research-use-only disclaimers and says products are not approved for human or animal consumption or therapeutic, diagnostic, or medicinal use.
• Thrive Rx - Homepage: Thrive Rx says care is delivered by AHPRA-registered practitioners through TGA-compliant telehealth, with prescriptions not guaranteed.
• ViCorpus - Homepage: ViCorpus lists SARMs/PCTs, Peptides, BPC-157, bacteriostatic water, and third-party-testing language on its public homepage.
• Platinum Research Compounds - Homepage: Platinum Research Compounds presents itself as a SARMs and peptides supplier and lists products including BPC-157, TB-500, IGF-1 LR3, CJC 1295 DAC, Ipamorelin, Retatrutide, Epitalon, MOTS-C, Tesamorelin, and NAD+.
• SARMs Australia - Homepage: SARMs Australia resolves but redirects Australian requests to a geoblocked page in this capture, so product-level evidence remains pending.
• Peptides Direct - Homepage: Peptides Direct says its medical team specialises in Australian peptides, medication, and supplements and describes registration, screening, treatment plan, compounding, and dispatch.
• Peptides Direct / RegenMed - Terms: The terms page says Peptides Direct by RegenMed is owned and operated by COSMETICS 2U PTY LTD.
• SARM Nation - Homepage: SARM Nation presents SARMs and peptides for laboratory research with third-party verified, batch-specific COA language and Australian dispatch claims.
• ClaraScience - Homepage: ClaraScience presents itself as Australian owned, research-use-only, batch verified, HPLC tested, and shipped from an Australian warehouse.
• PeptiSlim Australia - Homepage: PeptiSlim Australia says research peptides are delivered from Australia with COAs, batch numbers, HPLC verification, Express Post, and card checkout.
• Peptides Australia - Homepage: Peptides Australia is tracked as a Cloudflare-protected evidence queue because direct capture returned a protection response in this pass.
• Peptide Centre - Homepage: Peptide Centre publishes a peptide catalogue including BPC-157, TB-500, GHK-Cu, MOTS-C, NAD+, GLP peptides, growth-hormone peptides, and blends.
• Peptides Direct Australia - Homepage: Peptides Direct Australia presents a VIC-dispatched research peptide storefront with retatrutide, tirzepatide, BPC-157, GHK-Cu, starter kits, and AUD pricing.
• CompletePeptides - Homepage: CompletePeptides presents Australian fulfilment, independently tested batches, published COAs, ISO 17025 lab language, cold-chain shipping, and 48-hour dispatch claims.
• OzTideLab - Homepage: OzTideLab presents Australian-owned research peptide supply, HPLC-verified purity of 98% or higher, and domestic shipping claims.
• Aussie Peptides - Homepage: Aussie Peptides presents local Australian stock, same-business-day dispatch, COA every batch, and HPLC-purity claims.
• BT-7 - Homepage: BT-7 publishes research peptide category navigation, 24-hour dispatch language, third-party-testing language, and a reconstitution calculator.
• Research Chems Australia - Homepage: Research Chems Australia states the business has now closed and says orders and pre-orders placed before closing will be fulfilled.
• Pillar Research - Homepage: Pillar Research presents a launching-soon Australian research peptide storefront with HPLC, mass-spectrometry, batch-specific COA, Australian stock, and same-day dispatch claims.
• PeptideX - Homepage: PeptideX homepage metadata says it sells research peptides online in Australia with 99%+ purity, GMP-manufactured peptides, batch-specific COAs, and fast Australia-wide shipping.
• Aus Bio Peps - Homepage: Aus Bio Peps presents Australian research peptide supply with 99%+ purity via HPLC and MS testing, express shipping, local support, and secure ordering claims.
• VantaLab - BPC-157 product page: VantaLab's BPC-157 product page shows research-use-only language, 99%+ purity, COA included, Express Post, visible pricing, and a certificate-link surface.
• Southern Labs - Homepage: Southern Labs presents research-use-only peptides with same-day Adelaide dispatch, COA included, bundle stacks, and HPLC purity claims.
• PepC.Labs - Homepage: PepC.Labs presents Australian research peptides with ABN, same-day Sydney dispatch, COA every batch, and 99%+ HPLC purity claims.
• NSW Government - Chargebacks: NSW Government explains chargebacks for card transactions, including situations where goods or services were not received or were not as described.
• Everwell Medical - Homepage: Everwell Medical presents Australian research peptides with 98%+ purity, third-party lab testing, COA with every batch, shipment protection, and AU-wide shipping claims.
• Odezion - Homepage: Odezion presents research and pharmacy-grade peptide supply with up-to-date COAs, HPLC-MS testing, express shipping, and same-day dispatch claims.
• RetaLABS - Products page: RetaLABS presents AU-targeted GLP-1 research compounds with COA-backed, manufacturer-verified, Express Post Australia-wide shipping language.
• Stackpure - Homepage: Stackpure presents global peptide shipping including Australia, 99% HPLC purity, independent COA every batch, cGMP certification, Bitcoin payment, and a stack-builder flow.
• PHYX - Homepage: PHYX presents longevity and personalised healthcare pathways across weight loss, anti-ageing, injury repair, muscle building, mood, sleep, gut, and sexual performance categories.
• Peptide Help Australia - Homepage: Peptide Help Australia presents itself as an independent information platform and says it does not sell, import, or supply peptides.
• Australian Business Register - ABN Lookup: The Australian Business Register provides ABN Lookup for checking registered business names, ABN status, and entity details.
• Ahpra - Register of practitioners: Ahpra provides public registration lookup for health practitioners in Australia.
• Pharmacy Board of Australia - Codes and guidelines: The Pharmacy Board of Australia publishes codes, guidelines, and practice resources relevant to pharmacy conduct and standards.
• TGA - Database of Adverse Event Notifications: TGA describes the DAEN as a public database of adverse event notifications for medicines and vaccines.
• TGA - How to search the DAEN medicines: TGA explains how to search DAEN medicine reports and cautions that reports should be interpreted carefully.
• TGA - Searching the Australian Register of Therapeutic Goods: TGA provides public ARTG search for registered, listed, and included therapeutic goods that can be supplied in Australia.
• TGA - Advertising basics for therapeutic goods: TGA guidance explains the basics of advertising therapeutic goods in Australia and why advertisers need to comply with therapeutic-goods advertising rules.
• TGA - Advertising prescription medicines and other restricted goods: TGA explains what therapeutic goods can and cannot be advertised to the public, including prescription medicines and other restricted goods.
• ACCC - Social media influencers sweep: ACCC announced a sweep of social media influencers to identify misleading testimonials and endorsements.
• ACCC - Social media influencer testimonials guidance: ACCC guidance covers social media influencer testimonials and endorsement-risk signals for businesses and creators.
• TGA - Personal Importation Scheme: TGA says the Personal Importation Scheme applies only when all conditions are met, including personal or immediate-family use, prescription or written authority for prescription-only medicines, and the 3-month-per-order limit.
• TGA - BPC-157 final scheduling decision: TGA final decision created a Schedule 4 entry for BPC-157 in the Poisons Standard.
• TGA - PIED scheduling decision excerpt: TGA scheduling material lists CJC-1295, pralmorelin/GHRP-2, GHRP-6, growth hormone releasing hormones, GHRPs, GHSs, hexarelin, ipamorelin, thymosin beta 4, TB-500, and fibroblast growth factors in Schedule 4 and Appendix D Part 5.
• TGA - Poisons Standard overview: TGA explains that the Poisons Standard classifies medicines and poisons into schedules reflecting risk and recommended controls.
• TGA - NSW $2,664 import infringement: TGA issued a $2,664 infringement notice to a NSW-based medical practitioner for alleged unlawful importation of a prescription-only medicine.
• TGA - Caruso's Natural Health 2024 infringement notices: TGA issued five infringement notices totalling $82,500 to Caruso's Natural Health Pty Ltd for alleged failure to hold evidence supporting therapeutic uses in listed medicines.
• Grand View Research - Australia Peptide Therapeutics Market Size & Outlook: Public page states Australia peptide therapeutics revenue of US$1,906.3M in 2025, projected US$3,711.1M by 2033, at 7.8% CAGR from 2026 to 2033.
• McDermott Will & Schulte - Peptides Under the Microscope, April 2026: Presentation cites global peptide therapeutics at US$140.86B in 2025 and US$294.58B projected for 2033.
• TIME - What to Know About Anti-Aging Peptide Shots Flooding Social Media: Reports that wellness enthusiasts, biohackers, influencers, and celebrities are driving mainstream peptide attention while many products remain grey-market or unapproved.
• The Week - The regulation issues with grey-market peptides: Summarizes reporting that US imports of hormone and peptide compounds from China reached US$328M in the first three quarters of 2025, up from US$164M in the prior-year period.
• GZERO Media - How China is supplying America's biohacking craze: Reports the same near-doubling of US hormone and peptide compound imports from China in 2025.
• NPR / The Public's Radio - Influencers are promoting peptides: Reports influencer-driven peptide promotion and uncertainty around science, income disclosures, and product claims.
• Looksmaxxing exposes the darker side of glow-up culture: Reports a Brandwatch analysis of more than 806,000 looksmaxxing mentions from September 2025 to early 2026, with mostly negative sentiment.
• Hone Health - 26 Longevity Trends That Will Define 2026: Lists peptides and regenerative aesthetics as watched 2026 longevity and recovery trends.